2020 Abstract Submission Guidelines


Submit your Late-Breaking Abstract Here

Late Breaking Submission Criteria:

  • Late Breaking Submissions will be accepted approximately 4 weeks prior to the conference

  • Reports recent trial results with major impact in the neuromuscular disease community

  • A late-breaking abstract should contain new information. It may comprise either results that were not yet known, or fully available, on the regular abstract submission deadline, December 16, 2019. It is not intended to be merely an extension of the general submission deadline.

  • The data in the abstract must not be published prior to the start of the MDA conference on March 22,2020.

  • Late Breaking Abstracts will undergo MDA review

Topics for Late Breakers:

  • Clinical: Clinical Trials

  • Clinical: Gene targeted therapies

  • Clinical: Genetic Testing

MDA 2020 Embargo Policy

The embargo on all abstracts accepted for the 2020 MDA Clinical & Scientific Conference lifts on the date and time the abstract is publicly released by MDA.

While authors may publish the fact that their abstract has been selected for inclusion in the conference program, data from the abstract may not be shared in any form (print, broadcast or online publication, media release or conference presentation) prior to its official presentation at MDA 2020. Authors retains copyright of his or her abstract and poster. 

Encores are permitted provided that: (i) copyright requirements from the initial conference are respected and (ii) prior presentations are disclosed.